Expression of immunohistochemical markers of progression in pre-cancerous and cancerous human colon: Correlation with serum vitamin D levels

Anticancer Research

Volumn 35, Issue 3, 2015, Pages 1513-1520

  Juniku Shkololli, Argjira ^a,b   Manxhuka Kerliu, Suzana ^a   Ahmetaj, Halil ^a   Khare, Vineeta ^c   Zekaj, Sadik ^b  

^a UNIVERSITY CLINICAL CENTER OF KOSOVO   (Serbia)

^b Department of Gastrohepatology ^*  (Serbia)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ki67; Malignant and benign colon tumors; P53; PAK1; Vitamin D; catenin

Indexed keywords

25 HYDROXYVITAMIN D; BETA CATENIN; BIOLOGICAL MARKER; KI 67 ANTIGEN; P21 ACTIVATED KINASE 1; PROTEIN P53; VITAMIN D; 25-HYDROXYVITAMIN D; CTNNB1 PROTEIN, HUMAN; P21 ACTIVATED KINASE; PAK1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; COLON TUMOR; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; COLORECTAL POLYP; COLORECTAL SURGERY; COLORECTAL TUMOR; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GASTROINTESTINAL DYSPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PRECANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; STAINING; TISSUE SECTION; TUMOR DIFFERENTIATION; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; CELL NUCLEUS; CHEMISTRY; DISEASE COURSE;

ADULT; BETA CATENIN; BIOLOGICAL MARKERS; CELL NUCLEUS; COLONIC NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; P21-ACTIVATED KINASES; PRECANCEROUS CONDITIONS; TUMOR SUPPRESSOR PROTEIN P53; VITAMIN D;

EID: 84924993368     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Smith G, Carey FA, Beattie J, Wilkie MJV, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ and Wolf CR: Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. PNAS 99(14): 9433-9438, 2002.
2. Pereira F, Larriba MJ and Munoz A: Vitamin D and Colon Cancer. Endocrine-Related Cancer 19: R51-R71, 2012.
3. Tangrea J, Helzlouer K, Pietinen P, Taylor P, Hollis B, Virtamo J and Albanes D: Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Cancer Causes Control 8: 615-625, 1997.
4. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK and Gorham ED: Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 2: 1176-1178, 1989.
5. Wu K, Willett WC, Fuchs CS, Colditz GA and Giovannucci E: Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst 94: 437-446, 2000
6. Nittke T, Kallay E, Manhardt T and Cross HS: Parallel elevation of colonic 1, 25-dihydroxyvitamin D3 levels and apoptosis in female mice on a calcium-deficient diet. Anticancer Research 29: 372-3732, 2009.
7. Cross HS and Kallay E: Regulation of the Colonic Vitamin D System for prevention of tumor progression: an update. Future Oncol. 5(4): 493-507, 2009.
8. Ma Y, Trump DL and Johnson CS: Vitamin D in combination cancer treatment. J Cancer 1: 101-107, 2010.
9. Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D and Nickelsen T: A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 86: 1212-1221, 2001.
10. Bises G, Kallay E, Weiland T, Wrba F, Wenzi E, Bonner E, Kriwanek S, Obrist P, Cross HS: 25-Hydroxyvitamin D3-1-alpha-hydroxylase expression in normal and malignant human colon. J Histochem Cytochem. 52(7): 985-9, 2004.
11. Cross HS: Vitamin D Metabolism and Colon Cancer Pathogenesis. CML-Colorectal Cancer 3(4): 71-9, 2010.
12. Peterlik M and Cross HS: Vitamin D and Calcium Deficits Predispose for Multiple Chronic Diseases. Eur. J. Clin. Invest. 35(5): 290-304, 2005.
13. Stanley R. Hamilton and Lauri A. Aaltonen: TNM staging of tumors of the colon and rectum. In: WHO Organization Clas-sification of Tumours. Pathology & Genetics. Tumors of the Digestive System. IARC Press, Lyon, France, pp. 104: 2000.
14. Wanitsuwan W, Kanngurn S, Boonpipattanapong T, Sangthong R and Sangkhathat S: Overall Expression of β-catenin Outperforms its Nuclear Accumulation in Predicting Outcomes of Colorectal Cancers. World J Gastroenterol. 14(39): 6052-6059, 2008.
15. Wong SCC, Lo ESF, Chan AKC, Lee KC and Hsiao WL: Nuclear β-catenin as a Potential Prognostic and Diagnostic Marker in Patients with Colorectal Cancer from Hong Kong. Mol Pathol. 56: 347-352, 2003.
16. Behrens J: The Role of Wnt Signaling Pathway in Colorectal Tumorigenesis. Biochem Soc T. 33(4): 672-675, 2005.
17. Pendas-Franco N, Aguilera O, Gonzalez-Sancho JM and Munoz A: Vitamin D and Wnt/β-catenin Pathway in Colon Cancer: Role and Regulation of DICKKOPF Genes. Anticancer Research 28: 2613-2624, 2008.
18. Larriba MJ, Valle N, Palmer HG, Ordonez-Moran P, Alvarez-Diaz S, Becker K-F, Gamallo C, Garcia de Herreros A, Gonzalez-Sancho JM and Munoz A: The Inhibition of Wnt/β-catenin Signalling by 1alpha, 25-dihydroxyvitamin D3 is Abrogated by Snail 1 in Human Colon Cancer Cells. Endocr Relat Cancer 14: 141-151, 2007.
19. Jamieson C, Sharma M and Henderson BR: Targeting the β-catenin nuclear transport pathway in cancer.Semin Cancer Biol. 27: 20-9. 2014
20. Ye DZ and Field J: PAK Signaling in Cancer. Cellular Logist. 2: 105-116, 2012.
21. Li LH, Zheng MH, Luo Q, Ye Q, Feng B, Lu AG, Wang ML, Chen XH, Su LP and Liu BY: P21-activated Protein Kinase 1 Induces Colorectal Cancer Metastasis Involving ERK Activation and Phosphorylation of FAK at Ser-910. Int J Oncol. 37(4): 951-62, 2010.
22. He H, Huynh N, Liu KH, Malcontenty-Wilson C, Zhu J, Christophi C, Shulkes A and Baldwin GS: P-21 Activated Kinase I Knockdown Inhibits β-catenin Signalling and Blocks Colorectal Cancer Growth. Cancer Lett. 317(1): 65-71, 2012.
23. Zhu G, Wang Y, Huang B, Liang J, Ding Y, Xu A and Wu W: A Rac/PAK1 Cascade Controls β-catenin Activation in Colon Cancer Cells. Oncogene 31(8): 1001-12, 2012.
24. Ong CC Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, Turley H, O'Brien T, Vucic D, Harris AL, Belvin M, Friedman LS, Blackwood EM, Koeppen H and Hoeflich KP: Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. PNAS 108: 7177-7182, 2011.
25. Kraiss S, Spiess S, Reihsaus E and Montenarh M: Correlation of Metabolic Stability and Altered Quaternary Structure of Oncoprotein p53 with Cell Transformation. Exp Cell Res 192: 157-164, 1991.
26. Takayama T, Miyanishi K, Hayashi T, Sato Y and Niitsu Y: Colorectal cancer: Genetics of Development and Metastasis. J Gastroenterol. 41: 185-92, 2006.
27. Molaei M, Mansoori BK, Ghiasi S, Nemati F, Almasi S, Fatemi SR, Motlagh AG and Zali MR: Cancerogenesis in Colorectal Neoplasms: Evidence From Early Onset Colorectal Cancer. Clin Cancer Investig J. 1: 57-64, 2012.
28. Poller DN, Baxter KJ and Sepherd NA: p53 and Rb1 protein Expression: Are they prognostically Useful in Colorectal Cancer? Br J Cancer 75: 87-93, 1997.
29. Georgescu CV, Saftoiu A, Georgescu CC, Ciurea R and Ciurea T: Correlations of Proliferation markers, p53 Expression and Histological Findings in Colorectal Carcinoma. J Gastrointestin Liver Dis. 16: 133-139, 2007.
30. Oshima TC, Iriva K and Forones NM: Ki-67 as a Prognostic Marker in Colorectal Cancer but not in Gastric Cancer. Neoplasm 5: 420-4, 2005.